ClinicalTrials.gg
CompletedNCT00504335Updated Mar 17, 2015

Safety and Pharmacokinetic Study of BIO 300 Capsules

A Phase 1 interventional study of BIO 300 Capsules in Acute Radiation Syndrome, sponsored by Humanetics Corporation. Completed. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-17.

Sponsored by Humanetics Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This trial is designed to evaluate the safety and pharmacokinetics of BIO 300 capsules when administered orally to healthy male and female volunteers. BIO 300 is expected to be safe for use starting at 500 mg.

Read the detailed description

This clinical trial will assess the safety and PK of BIO 300 capsules at doses expected to deliver a radioprotective or therapeutic effect in humans. Humanetics is planning to conduct this Phase I, single dose, dose-escalation (500, 1000, 1500, and 2000 milligrams) study of the safety, tolerability and pharmacokinetics of BIO 300 by recruiting approximately 24 healthy men and women between the ages of 18 and 64 to be enrolled in cohorts of 6 subjects per group. The first cohort will receive one 500 mg BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting at a clinic skilled in this type of Phase I trial. Blood samples will be analyzed for BIO 300 levels, hematology, chemistry, lipid profiles, phosphorus, clotting factors and fibrinogen as well as pancreatic lipase and amylase. Urinalysis will assess kidney function as well as creatinine clearance and BIO 300 clearance. All subjects will be monitored for adverse events and the safety of BIO 300 capsules will be evaluated in this setting. After review of all safety information and provided no clinically significant negative findings are revealed, the second cohort will be treated with 1000mg BIO 300 (two 500mg capsules) using the same PK sampling program. Again safety concerns will be reviewed and provided no clinically significant negative findings are revealed, the third and fourth cohort will be treated with 1500 and 2000 mg, respectively, of BIO 300 using the same PK sampling program.

02

Conditions studied

  • Acute Radiation Syndrome

Browse trials for

Keywords

  • Acute Radiation Syndrome
  • Hematopoietic Syndrome
  • Radiation Injury
  • BIO 300
03

In context

Radiation Injuries

328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.

This study's enrollment of 24 is below the median of 72 across 216 interventional studies indexed under Radiation Injuries.

Browse Radiation Injuries studies →

Lead sponsor

Humanetics Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects, age 18-64, who have signed the consent form

    • Subjects with a (BMI) 18-30 kg/m2
    • Subjects who are willing to abstain from sex or use a barrier method of (Women 1 week, Men 4 months after leaving the trial)
    • Subjects with a negative pregnancy test and drug screen
    • Subjects with laboratory values within normal limits (CBC/differential, CMP, enzymes, , vital signs, urinalysis)
    • Subjects with ability to comprehend and complete the questionnaires and forms
    • Subjects who are likely to comply with study procedures and test article consumption
    • Subjects whose schedules permit a 10-12 hour stay in the clinic followed by daily evaluations for one week (7 days)
    • Subjects who are available for a 14-day follow up phone call (women) and 4-month follow up phone call (men).
    • Subjects who are likely to abstain from taking unauthorized medications or supplements or participating in any other clinical trial or experimental treatment during this trial
    • Subjects who are likely to follow the low isoflavone diet program

Exclusion criteria

Exclusion Criteria:

    • Subjects with any allergic reaction or sensitivity to soy, isoflavones, or any component of the test article product

      • Subjects who consume >5 alcoholic beverages per week
      • Subjects who are pregnant, lactating, or at risk of becoming pregnant
      • Subjects who have blood (or urine) levels outside the normal range for any of the hepatic, renal, hematologic, lipid or coagulation parameters measured.
      • Subjects on Hormone Replacement Therapy or Pills within the past three months.
      • Subjects on any other clinical trial or experimental treatment in the past 3 months
      • Subjects with a history of diabetes (Type 1 or Type 2 diabetes mellitus) or other endocrine disorders, uncontrolled hypertension, prior cerebrovascular accident or seizure disorder, cardiovascular, hepatic or renal disease, active cancer, hematologic disorder, thromboembolic disease, or infection.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    500 BIO 300 capsule

    The first cohort will receive one 500 BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting

    Drug: BIO 300 Capsules

  • Experimental
    1000 BIO 300 capsule

    the second cohort will be treated with 1000 mg BIO 300 using the same PK sampling program

    Drug: BIO 300 Capsules

  • Experimental
    1500 BIO 300 capsule

    the third cohort will be treated with 1500 mg BIO 300using the same PK sampling program

    Drug: BIO 300 Capsules

  • Experimental
    2000 BIO 300 capsule

    the forth cohort will be treated with 2000 mg BIO 300using the same PK sampling program

    Drug: BIO 300 Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Safety as assessed by lab work and adverse event monitoring

    Time frame: 1 month for females & 4 months for males

Secondary outcomes

  1. Pharmacokinetic assessment by analyzing patient serum for free and total BIO 300 content at multiple time points.

    Time frame: 7 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Sep 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2007
First posted
Jul 20, 2007
Start
Jun 2007
Primary completionActual
Sep 2007
CompletionActual
Oct 2007
Last update
Mar 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00504335
Lead sponsor
Humanetics Corporation
Collaborators
United States Department of Defense
First posted
Jul 20, 2007
Start date
Jun 2007
Primary completion
Sep 2007
Completion
Oct 2007
Last update
Mar 17, 2015

Study contacts

John L Zenk, MD
principal investigator · Humanetics Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Genistein-based BIO 300

Start the discussion